알테오젠의 파트너사 MSD(미국/캐나다 내 Merck)는 'KEYTRUDA QLEXTM'와 KRAS G12C 억제제 calderasib의 병용 임상3상을 비소세…
Merck.com
Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-…
Third Phase 3 trial in Merck’s KANDLELIT clinical development program, which is investigating calderasib in KRAS G12C-mutant cancers across multiple tumor types and treatment settings Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELI…
